Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Zynerba Pharmaceuticals Inc (ZYNE)

NASDAQ
Currency in USD
Disclaimer
1.300
0.000(0.00%)
Real-time Data

ZYNE Comments

I'm not happy with the sale, it would have been better if the company continued the introduction and got off the ship after a successful FDA decision, then the $8 would have been fine, there is nothing to do but say goodbye to the comrades, good luck to everyone in other pharmaceuticals.
bye bye Zyne.
On the day of the buyout offer, it was deposited at 1.37, it did not go away, I withdrew it the next day, there is no point in charting, here the news is measured at 300%, so the stop is not, either to give, or upon agreement when selling the patent protection, or the introduction request upon submission to the FDA. Zero still has a 10-20% chance, the rest shares the band between $2.5 and $10, for a company with 25 employees, if you manage to sell the license, the revenue will reach $1 billion around 2027-28, the royalty would be 20% , this story would not move anything at Pfizer, there are 83,000 employees. We have to wait for the sale of the Zygel distribution, in the form when the royalty payment is made every 1/4th year for 18 years, then we would see a day of +300% again, these $60 and +140 m promise little. Don't worry, don't watch the news, patience everyone!
I found 3 lawfirms that are investigating potential Board's lack of diligence regarding Harmony deal since there are lots of milestones to achive for ZYGEL to get 140 mln additional price for shareholders. Acording to one of the annoucments there are certain guarantees for board members for theirs paychecks while extra payment for shareholders are gloomy regarding strict conditions for ZYGEL
Slow down, Amigo, if they don't sell it, but sell it directly after the launch, then not $140m once, but even $200m royalties per year after traffic starts up for 15 years, when the protection expires, which is 18 years anyway, you're a beginner you are a competitor in this pharmaceutical profession, I will not take you on as a student-:)XD
just sayin if some is interested :)
I hold it firmly, I have no intention of selling it, the next +300% day would be the submission of the FDA registration application, do the math, I assume a royalty transfer of $3/share for the sale of the distribution, 25 employees will not live up to it, a fabulous dividend would come, the current exchange rate double, there is still the possibility of a fall, but the chance of this has greatly decreased. Patience everyone, it's a patience game now.
Írja I looked at ZYNERBA as either zeroing out, maybe 10x, it is working on the launch of an ointment containing cannabis, in relation to rare mental illnesses, the launch was promised next year, I considered it possible to reach even $1 billion in revenue, if it were to sell, then 3 years after the launch after peaking, $200 million/year in royalties would arrive. Today, the hard rock hit, a buyout offer of $1.1059 in cash + $140 million in milestones upon successful launch, Cash/share 84 cents, it also traded at an abnormal 30 cents, 1/3 of the stock, so the buyer would only pay 26 cents including kp, working capital covers short-term liabilities 5x, it can last until the introduction, if it comes together at the FDA, then + 140 is in play, which is 3x even from here, exchange rate +277% now, but the real big money, 3x would also multiply , if they don't give it and sit in the gold mine. I've always loved and felt for pharmaceuticals, until now Cariprazine launch in September 2015, Allergan buyout, BIOGEN Alzheimer's story, this would be the icing on the cake.meg véleményét a Zynerba Pharmaceuticals Inc.-ről
haha ZYNE can't push reverse stock split because of the absence of shareholders on meetings xD Zyne became garbage stock
-:)XDDDDDDDDDD
Zynerba intends to seek approval of a reverse stock split at its Annual Meeting of Stockholders in June (Annual Meeting), which it would effect any time prior to November 1, 2023. Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting. The primary objective of implementing a reverse split is to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Company’s Board believes that effecting the reverse split would increase the price of our common stock which would, among other things, help the Company to: Meet certain continued listing requirements of the Nasdaq Capital Market; Appeal to a broader range of investors to generate interest in the Company; and Improve perception of the Company’s common stock as an investment security.
long story short, zyne performes so "good" that would be delisted
and now money burs faster and faster bye bye zyne
🤮🤮🤮🤮
Bankruptcy won't be long now I guess 😔
with money outflow during high inflation they are on the edge . last presentation available on their site show plans to establish zygel to the market in 2026... with 18mil in cap it won't last that longo
on seeking aplha there is a news about positive impact of Zygel on fx patients
https://www.zynerba.com/zynerba-pharmaceuticals-announces-positive-long-term-data-from-phase-2-inspire-trial-in-22q11-2-deletion-syndrome-at-the-annual-meeting-of-the-american-college-of-neuropsychopharmacology/
Burning money just to keep floating untill reconnnet results..
https://www.zynerba.com/zynerba-pharmaceuticals-presents-positive-data-from-phase-2-inspire-trial-in-22q-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-24th-international-research-symposium/
https://www.zynerba.com/zynerba-pharmaceuticals-enters-into-equity-purchase-agreement-for-up-to-20-million-with-lincoln-park-capital/ In case you missed it:)
I wish i could affort buying more on this price...
in this market condition and inflation ZYNE is on its way to default b4 FX reconnect results:D Good Job:D
They are getting money from instututionals for the cash flow, dont think they wont get it again to survive till sales start
Did you spot that ZYNE is no longer calling itself in bio "leader" in treating rare/near-rare diseases?:D
orphan drug registration is a bit fail for ZYNE - orphan drug registration is granted for drugs for diseases so rare that its economically senseless to conduct proper research and its known that production costs will not be covered with incomes. So for "leader" in treatment rare and near-rare diseases it's like a cofirmation that Zyne won't make money...
below 2.7 its a freeway to 0.001 per share
I still think its a perfect bet, but it became more longterm cause of FDA pro-GW position
Right now ZYNE price tests still important support price lvl. 3.3$ had been tested 4 times and for the 5th time two days ago. Its important technically for one more reason, that going up from here could lead to breach of downtrend which last practically from the very begininng of ZYNE presence on NSDAQ. Goung up from here would make downtrend looks weaker with lower highs but also higher lows. Overall on the chart Zyne still needs much more trust from investors.
Dunno how to paste charts from other sources so ...
Im suprised that Zyne is lagging so much alike cannabis market even with absolutely different profile and product. Disappointing tbh.
ah and only thing we wait for is that they spent less than consensus forsee, and imo it's practically out of the reach with whole market fluctuating especially basic materials. What you think?
Do you think Zyne will seek FDA approval for conditions other than f-x before Reconnect results?k is it possible Zyne files for FDA acceptantra
ouch two more years till reconnect results...
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.